论文部分内容阅读
目的了解鲍曼不动杆菌临床感染分布和耐药状况。方法应用法国梅里埃VITEK 2微生物鉴定和药敏系统对收集自湖北省荆州市中心医院2008年1月-2009年1月的临床标本进行细菌培养鉴定及药敏分析,用WHONET 5分析试验结果。结果一年间共分离鲍曼不动杆菌104株,痰标本分离率最高达97.12%,主要引起重症监护病房(ICU)患者的下呼吸道感染。该菌耐药性极其严重,对16种常用抗菌药物的耐药率除头孢他啶外,均大于60%。其中25株对16种抗菌药物全部耐药,为泛耐药菌株。结论鲍曼不动杆菌感染以重症监护病房最常见,且多重耐药明显。临床应加强检测,合理使用抗生素,以提高疗效和减缓耐药株的产生。
Objective To understand the clinical distribution and drug resistance of Acinetobacter baumannii. Methods The clinical samples from January 2008 to January 2009 in Jingzhou Central Hospital of Hubei Province were identified by bacterial identification and drug susceptibility analysis using the Michelia VITEK 2 Microbial Identification and Drug Sensitive System in France. The results were analyzed by WHONET 5. Results A total of 104 strains of Acinetobacter baumannii were isolated in one year. The separation rate of sputum specimens was up to 97.12%. The main cause was lower respiratory tract infection in intensive care unit (ICU) patients. The bacteria resistance is extremely serious, the resistance rate of 16 commonly used antibiotics except ceftazidime, are greater than 60%. Among them, 25 strains were completely resistant to 16 kinds of antibiotics and were pan-resistant strains. Conclusion Acinetobacter baumannii infection is the most common in intensive care unit and its multi-drug resistance is obvious. Clinical tests should be strengthened, the rational use of antibiotics to improve efficacy and reduce the generation of resistant strains.